HLA and skin cancer;HLA e câncer de pele

Anais Brasileiros de Dermatologia

Volumn 87, Issue 1, 2012, Pages 9-18

  Bonamigo, Renan Rangel ^a   de Carvalho, André Vicente Esteves ^b   Sebastiani, Vanessa Raquel Zaleski ^c   da Silva, Cristina Martino ^b   Pinto, Angela Caroline de Zorzi ^b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

^c Santa Casa de Misericordia de Porto Alegre   (Brazil)

Author keywords

Basal cell; Carcinoma; HLA antigens; Melanoma; Neoplasms; Skin neoplasms; Squamous cell

Indexed keywords

HLA A11 ANTIGEN; HLA ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA B27 ANTIGEN; HLA DR ANTIGEN; HLA DR1 ANTIGEN; HLA DR4 ANTIGEN; HLA DR7 ANTIGEN; TUMOR ANTIGEN;

AGING; ANTIGEN EXPRESSION; BASAL CELL CARCINOMA; CANCER RISK; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; HLA SYSTEM; HUMAN; IMMUNOSURVEILLANCE; MELANOMA SKIN CANCER; NON MELANOMA SKIN CANCER; PAPILLOMAVIRUS INFECTION; PATHOGENESIS; REVIEW; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; SUN EXPOSURE; ULTRAVIOLET RADIATION;

EID: 84862161357     PISSN: 03650596     EISSN: 18064841     Source Type: Journal    
DOI: 10.1590/S0365-05962012000100001     Document Type: Review

References (38)

1. Dahl M. Immunodermatology. 2nd ed: Chicago: Yerbook Medocal Publishers; 1988.
2. Klein J, Sato A. The HLA System. First of Two Parts. N Engl J Med. 2000;343:702-9.
3. Abbas A, Lichtman A. Captura e Apresentação do antígeno aos linfócitos. In: Abbas A, Lichtman A, editors. Imunologia básica: funções e distúrbios do sistema imunológico. 2 ed. Rio de Janeiro: Elsevier; 2007. p. 45.
4. Abbas A, Lichtman A. Respostas imunes mediadas por células. In: Abbas A, Lichtman A, editors. Imunologia básica: Funções e distúrbios do sistema imunológico. 2 ed. Rio de Janeiro: Elsevier; 2007. p. 91.
5. Baker R, Warrens A. The biology of histocompatibility complex molecules-I. In: Lechler R, Warrens A, editors. HLA in health and disease. 2nd ed. London: Academic Press; 2000. p. 51-72.
6. Klein J, Sato A. The HLA System: Second of Two Parts. N Engl J Med. 2000;343:782-6.
7. Donadi E. Aspectos moleculares do complexo principal de histocompatibilidade: como entender a associação entre o sistema HLA e as doenças reumáticas. Rev Bras Reumatol. 2001;41:225-36.
8. Opelz G. HLA and Transplantation-II: The Role of HLA Matching in clinical Transplantation. In: Lechler R. WA, editor. HLA in Health and disease. 2nd. ed. London: Academic Press; 2000. p. 14.
9. Paul P, Rouas-Freiss N, Khalil-Daher I, Moreau P, Riteau B, Le Gal FA, et al. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci U S A. 1998;95:4510-5.
10. Rigel DCC, Carucci J, Wharton J. Actinic Keratosis, Basal Cell Carcinoma and Squamous Cell Carcinoma. In: Bolognia JLJJ, Rapini R, editors. Dermatology. London: Mosby Elseviewer; 2008. p. 21.
11. Stern R. The mysteries of geographic variability in nonmelanoma skin cancer incidence. Arch Dermatol. 1999;135:843-4.
12. Viac J, Chardonnet Y, Chignol MC, Schmitt D. Papilloma viruses, warts, carcinoma and Langerhans cells. In Vivo. 1993;7:207-12.
13. Purdie KJ, Surentheran T, Sterling JC, Bell L, McGregor JM, Proby CM, et al. Human papillomavirus gene expression in cutaneous squamous cell carcinomas from immunosuppressed and immunocompetent individuals. J Invest Dermatol. 2005;125:98-107.
14. Glover MT, Bodmer J, Bodmer W, Kennedy LJ, Brown J, Navarrete C, et al. HLA antigen frequencies in renal transplant recipients and non-immunosuppressed patients with non-melanoma skin cancer. Eur J Cancer. 1993;29A:520-4.
15. Myskowski PL PM, Schorr E, Dupont B, Safai, B. Human leukocyte antigen associations in basal cell carcinoma. J Am Acad Dermatol. 1985;12:997-1000.
16. Cerimele D, Contu L, Carcassi C, Costa G, La Nasa G, Sanna E, et al. HLA and multiple skin carcinomas. Dermatologica. 1988;176:176-81.
17. Nakamura T, Kageshita T, Hirai S, Kimura T, Yoshii A, Ono T, et al. [Expression of HLA-class I and II antigens on basal cell carcinoma]. Nippon Hifuka Gakkai Zasshi. 1990;100:1431-5.
18. Czarnecki D, Lewis A, Nicholson I, Tait B. Multiple basal cell carcinomas and HLA frequencies in southern Australia. J Am Acad Dermatol. 1991;24:559-61.
19. Czarnecki D, Meehan C, Lewis A, Nicholson I, Tait B. Age and multiple basal cell carcinomas in Australia. Int J Dermatol. 1991;30:713-4.
20. Czarnecki DB, Lewis A, Nicholson I, Tait B. Multiple nonmelanoma skin cancer associated with HLA DR7 in southern Australia. Cancer. 1991;68:439-40.
21. Czarnecki D, Lewis A, Nicholson I, Tait B, Nash C. HLA-DR1 is not a sign of poor prognosis for the development of multiple basal cell carcinomas. J Am Acad Dermatol. 1992;26:717-9.
22. Czarnecki D, Collins N, Chow P, Nicholson I, Tait B. Multiple basal cell carcinoma in tropical Australia. Int J Dermatol. 1992;31:635-6.
23. Czarnecki D, Nicholson I, Tait B, Meehan C. No HLA association with the early development of a single basal cell carcinoma. Dermatology. 1995;190:88.
24. Urosevic M, Dummer R. Immunotherapy for nonmelanoma skin cancer: does it have a future? Cancer. 2002;94:477-85.
25. Urosevic M, Dummer R. HLA-G in skin cancer: a wolf in sheep's clothing? Hum Immunol. 2003;64:1073-80.
26. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Picconi O, Boyle P, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer. 2005;41:45-60.
27. Nestle FO, Burg G, Fah J, Wrone-Smith T, Nickoloff BJ. Human sunlight-induced basal-cell-carcinoma-associated dendritic cells are deficient in T cell co-stimulatory molecules and are impaired as antigen-presenting cells. Am J Pathol. 1997;150:641-51.
28. Planelles D, Nagore E, Moret A, Botella-Estrada R, Vila E, Guillén C, et al. HLA class II polymorphisms in Spanish melanoma patients: homozygosity for HLA-DQA1 locus can be a potential melanoma risk factor. Br J Dermatol. 2006;154:261-6.
29. Marincola FM, Shamamian P, Rivoltini L, Salgaller M, Cormier J, Restifo NP, et al. HLA associations in the antitumor response against malignant melanoma. J Immunother Emphasis Tumor Immunol. 1995;18:242-52.
30. Lombardi ML, Mercuro O, Pirozzi G, Ionna F, Lombari V, Mozzillo N, et al. Molecular analysis of HLA DRB1 and DQB1 polymorphism in Italian melanoma patients. J Immunother. 1998;21:435-9.
31. Lulli P, Grammatico P, Brioli G, Catricala C, Morellini M, Roccella M, et al. HLA-DR and-DQ alleles in Italian patients with melanoma. Tissue Antigens. 1998;51:276-80.
32. Kageshita T, Naruse T, Hirai S, Ono T, Horikoshi T, Nakagawa H, et al. Molecular genetic analysis of HLA class II alleles in Japanese patients with melanoma. Tissue Antigens. 1997;49:466-70.
33. Bateman AC, Turner SJ, Theaker JM, Howell WM. HLA-DQB1*0303 and *0301 alleles influence susceptibility to and prognosis in cutaneous malignant melanoma in the British Caucasian population. Tissue Antigens. 1998;52:67-73.
34. Carretero R, Romero JM, Ruiz-Cabello F, Maleno I, Rodriguez F, Camacho FM, et al. Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy. Immunogenetics. 2008;60:439-47.
35. van Vreeswijk H, Ruiter DJ, Brocker EB, Welvaart K, Ferrone S. Differential expression of HLA-DR, DQ, and DP antigens in primary and metastatic melanoma. J Invest Dermatol. 1988;90:755-60.
36. Paul P, Cabestre FA, Le Gal FA, Khalil-Daher I, Le Danff C, Schmid M, et al. Heterogeneity of HLA-G gene transcription and protein expression in malignant melanoma biopsies. Cancer Res. 1999;59:1954-60.
37. Ugurel S, Rebmann V, Ferrone S, Tilgen W, Grosse-Wilde H, Reinhold U. Soluble human leukocyte antigen--G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy. Cancer. 2001;92:369-76.
38. Alves C, Vieira N, Meyer I, Oliveira-Alves C, Toralles MB, Oliveira MF. Antígenos de histocompatibilidade humanos e dermatologia: da pesquisa para a prática clínica. An Bras Dermatol. 2006;81:65-73.